CD19-targeted CAR-T Cell Therapy for MRD+ B-cell Malignancies After Autologous Stem Cell Transplantation

Inclusion Criteria:

1. Confirmed by pathological biopsy in patients with B-cell malignancies and treated byautologous stem cell transplantation.

2. Age 18 to 75 years old, both male and female;

3. Is expected to survive more than 3 months;

4. Physical condition is good: ECOG score≤2;

5. In group of four weeks before Canon imaging examination evaluation body tumor load,recommend line PET - CT examination.

6. General requirements autologous as basic, normal blood T lymphocytes in autologouscount must >= 0.2 x10^9 / L;

7. No obvious abnormal heart, liver, kidney, no large wounds that haven't healed on thebody;

8. Into groups to participate in voluntarily, good adherence, can cooperate testobservation, childbearing age women must be 7 days before starting treatment expertpregnancy test and the results were negative, and signed a written informed consentform.

Exclusion Criteria:

1. Organ failure, such as heart: Class III and IV; liver: to Child grading of liverfunction grade C; kidney: kidney failure and uremia stage; lung: symptoms of severerespiratory failure; brain: disorder of consciousness;

2. Existing serious acute infection, uncontrollable, or have fester sex and chronicinfection, wound in delay no more;

3. Patients with significant graft versus host disease (GVHD) after organ transplanthistory or allogeneic hematopoietic stem cell transplantation;

4. Systemic autoimmune diseases or immunodeficiency disease, patients with allergicconstitution;

5. Coagulation abnormalities and severe thrombosis;

6. Pregnancy and lactation women;

7. Any other chronic disease patients who have been treated with immune agents or hormonetherapy;

8. Patients who have participated in other clinical trials or other clinical trials inthe past 30 days;

9. The Investigator believe the patients should not participate in this experiment.